+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Metered Dose Inhalers Market by Product Type, Application, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2025-2034

  • PDF Icon

    Report

  • 346 Pages
  • June 2025
  • Region: Global
  • Allied Market Research
  • ID: 6218049
Description Jump to:
The metered dose inhalers market was valued at $10.08 billion in 2024 and is estimated to reach $18.40 billion by 2034, exhibiting a CAGR of 6.2% from 2025 to 2034.

A Metered Dose Inhaler (MDI) is a device commonly used to deliver medications directly to the lungs, primarily for conditions like asthma, COPD (chronic obstructive pulmonary disease), and other respiratory disorders. These inhalers consist of a pressurized canister containing medication, which is released through a mouthpiece when the canister is actuated. The medication is usually in the form of an aerosol or suspension that is inhaled during a breath, ensuring rapid absorption in the lungs. MDIs are widely preferred due to their compact design, ease of use, and ability to provide quick relief from symptoms like wheezing, coughing, and shortness of breath. In recent years, advances such as dose counters, breath-actuated mechanisms, and environmentally friendly propellants have enhanced the effectiveness and safety of MDIs. They play a critical role in both emergency and maintenance therapy for millions of patients worldwide, particularly in outpatient and home care settings.

Rise in aging population, improved compliance, environmental regulations, and generic availability are fueling steady growth in the global metered dose inhalers market. Moreover, initiatives taken by key industry players are further contributing to the market’s positive trajectory. For instance, in January 2023, the Hormosan Pharma GmbH (Hormosan), Lupin’s wholly-owned subsidiary in Germany, announced the launch of Luforbec 100/6 (beclometasone 100µg / for moterol 6µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Moreover, to reduce the environmental impact of inhalers, pharmaceutical companies are transitioning to low-global warming potential (GWP) propellants. For instance, Kindeva Drug Delivery is set to produce MDIs using propellants like HFA-152a and HFO-1234ze, which offer GWP reductions of up to 90% and 99.9%, respectively, compared to the traditional HFA-134a . In addition, artificial Intelligence (AI) is being utilized to optimize drug delivery. Machine learning algorithms analyze factors such as breathing profiles and disease status to adjust inhaler settings, ensuring targeted drug release to specific lung sites while minimizing side effects. With companies actively developing new formulations and expanding their product portfolios, the metered dose inhalers market is expected to continue witnessing robust growth in the coming years.

Segment Overview:

The metered dose inhalers market is segmented on the basis of product type, application, distribution channel, and region. On the basis of product type the market is segmented into conventional MDIs, and breath-actuated MDIs. On the basis of application, the market is segmented into asthma, COPD and others. On the basis of distribution channel, the market is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The major key players that operate in the global metered dose inhalers market are AstraZeneca, GlaxoSmithKline Pharmaceuticals Ltd, Chiesi Farmaceutici S.p.A., Cipla Ltd., Teva Pharmaceutical Industries, Lupin, AptarGroup, Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., and Zydus Lifesciences Limited.

Additional benefits you will get with this purchase are:

  • Quarterly update with the purchase of an enterprise license.
  • 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
  • Free version update with the purchase of an Enterprise User License.
  • 16 hours of analyst support.
  • 15% free customization (Equivalent to 3 working days of work, applicable once).
  • Free data pack (Excel) with the purchase of an Enterprise User License.
  • Free updated report if the report is 6-12 months old or older.
  • 24-hour priority response.
  • Free industry updates and white papers.

Further possible customization (additional cost and timeline):

  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Application

  • Asthma
  • COPD
  • Other

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Product Type

  • Conventional MDIs
  • Breath actuated MDIs

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • AstraZeneca
  • Cipla Ltd.
  • Teva Pharmaceutical Industries
  • Lupin
  • Boehringer Ingelheim International GmbH
  • Zydus Lifesciences Limited
  • Chiesi Farmaceutici S.p.A.
  • GlaxoSmithKline Pharmaceuticals Ltd
  • AptarGroup, Inc.
  • Sun Pharmaceutical Industries Ltd.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of respiratory diseases
3.4.1.2. Availability of generic and low-cost inhalers
3.4.1.3. Technological advancements in metered dose inhalers
3.4.2. Restraints
3.4.2.1. Challenges in Patient Awareness and Regulatory Approvals
3.4.3. Opportunities
3.4.3.1. Development of eco-friendly inhalers
CHAPTER 4: METERED DOSE INHALERS MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Conventional MDIs
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Breath actuated MDIs
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: METERED DOSE INHALERS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Asthma
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. COPD
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Other
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: METERED DOSE INHALERS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Product Type
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Product Type
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Product Type
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Product Type
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Product Type
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Product Type
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Product Type
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Product Type
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Product Type
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Product Type
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Product Type
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Product Type
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Product Type
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Product Type
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Product Type
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Product Type
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Product Type
7.4.5.5.2. Market size and forecast, by Application
7.4.5.5.3. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Product Type
7.4.5.6.2. Market size and forecast, by Application
7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Product Type
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Product Type
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Product Type
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Product Type
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Product Type
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2024
CHAPTER 9: COMPANY PROFILES
9.1. AstraZeneca
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. GlaxoSmithKline Pharmaceuticals Ltd
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Chiesi Farmaceutici S.p.A.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Cipla Ltd.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Teva Pharmaceutical Industries
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Lupin
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. AptarGroup, Inc.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Boehringer Ingelheim International GmbH
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Sun Pharmaceutical Industries Ltd.
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Zydus Lifesciences Limited
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
LIST OF TABLES
TABLE 1. GLOBAL METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 2. GLOBAL METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 3. METERED DOSE INHALERS MARKET FOR CONVENTIONAL MDIS, BY REGION, 2024-2034 ($MILLION)
TABLE 4. METERED DOSE INHALERS MARKET FOR CONVENTIONAL MDIS, BY REGION, 2024-2034 (MILLION UNITS)
TABLE 5. METERED DOSE INHALERS MARKET FOR BREATH ACTUATED MDIS, BY REGION, 2024-2034 ($MILLION)
TABLE 6. METERED DOSE INHALERS MARKET FOR BREATH ACTUATED MDIS, BY REGION, 2024-2034 (MILLION UNITS)
TABLE 7. GLOBAL METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 8. METERED DOSE INHALERS MARKET FOR ASTHMA, BY REGION, 2024-2034 ($MILLION)
TABLE 9. METERED DOSE INHALERS MARKET FOR COPD, BY REGION, 2024-2034 ($MILLION)
TABLE 10. METERED DOSE INHALERS MARKET FOR OTHER, BY REGION, 2024-2034 ($MILLION)
TABLE 11. GLOBAL METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 12. METERED DOSE INHALERS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024-2034 ($MILLION)
TABLE 13. METERED DOSE INHALERS MARKET FOR RETAIL PHARMACIES, BY REGION, 2024-2034 ($MILLION)
TABLE 14. METERED DOSE INHALERS MARKET FOR ONLINE PHARMACIES, BY REGION, 2024-2034 ($MILLION)
TABLE 15. METERED DOSE INHALERS MARKET, BY REGION, 2024-2034 ($MILLION)
TABLE 16. METERED DOSE INHALERS MARKET, BY REGION, 2024-2034 (MILLION UNITS)
TABLE 17. NORTH AMERICA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 18. NORTH AMERICA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 19. NORTH AMERICA METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 20. NORTH AMERICA METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 21. NORTH AMERICA METERED DOSE INHALERS MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 22. NORTH AMERICA METERED DOSE INHALERS MARKET, BY COUNTRY, 2024-2034 (MILLION UNITS)
TABLE 23. U.S. METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 24. U.S. METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 25. U.S. METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 26. U.S. METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 27. CANADA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 28. CANADA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 29. CANADA METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 30. CANADA METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 31. MEXICO METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 32. MEXICO METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 33. MEXICO METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 34. MEXICO METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 35. EUROPE METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 36. EUROPE METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 37. EUROPE METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 38. EUROPE METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 39. EUROPE METERED DOSE INHALERS MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 40. EUROPE METERED DOSE INHALERS MARKET, BY COUNTRY, 2024-2034 (MILLION UNITS)
TABLE 41. GERMANY METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 42. GERMANY METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 43. GERMANY METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 44. GERMANY METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 45. FRANCE METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 46. FRANCE METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 47. FRANCE METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 48. FRANCE METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 49. UK METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 50. UK METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 51. UK METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 52. UK METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 53. ITALY METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 54. ITALY METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 55. ITALY METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 56. ITALY METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 57. SPAIN METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 58. SPAIN METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 59. SPAIN METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 60. SPAIN METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 61. REST OF EUROPE METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 62. REST OF EUROPE METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 63. REST OF EUROPE METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 64. REST OF EUROPE METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 65. ASIA-PACIFIC METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 66. ASIA-PACIFIC METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 67. ASIA-PACIFIC METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 68. ASIA-PACIFIC METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 69. ASIA-PACIFIC METERED DOSE INHALERS MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 70. ASIA-PACIFIC METERED DOSE INHALERS MARKET, BY COUNTRY, 2024-2034 (MILLION UNITS)
TABLE 71. JAPAN METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 72. JAPAN METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 73. JAPAN METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 74. JAPAN METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 75. CHINA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 76. CHINA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 77. CHINA METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 78. CHINA METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 79. INDIA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 80. INDIA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 81. INDIA METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 82. INDIA METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 83. AUSTRALIA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 84. AUSTRALIA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 85. AUSTRALIA METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 86. AUSTRALIA METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 87. SOUTH KOREA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 88. SOUTH KOREA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 89. SOUTH KOREA METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 90. SOUTH KOREA METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 93. REST OF ASIA-PACIFIC METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 95. LAMEA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 96. LAMEA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 97. LAMEA METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 98. LAMEA METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 99. LAMEA METERED DOSE INHALERS MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 100. LAMEA METERED DOSE INHALERS MARKET, BY COUNTRY, 2024-2034 (MILLION UNITS)
TABLE 101. BRAZIL METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 102. BRAZIL METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 103. BRAZIL METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 104. BRAZIL METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 105. SAUDI ARABIA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 106. SAUDI ARABIA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 107. SAUDI ARABIA METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 108. SAUDI ARABIA METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 109. SOUTH AFRICA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 110. SOUTH AFRICA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 111. SOUTH AFRICA METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 112. SOUTH AFRICA METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 113. REST OF LAMEA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 ($MILLION)
TABLE 114. REST OF LAMEA METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024-2034 (MILLION UNITS)
TABLE 115. REST OF LAMEA METERED DOSE INHALERS MARKET, BY APPLICATION, 2024-2034 ($MILLION)
TABLE 116. REST OF LAMEA METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024-2034 ($MILLION)
TABLE 117. ASTRAZENECA: KEY EXECUTIVES
TABLE 118. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 119. ASTRAZENECA: PRODUCT SEGMENTS
TABLE 120. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 121. ASTRAZENECA: KEY STRATERGIES
TABLE 122. GLAXOSMITHKLINE PHARMACEUTICALS LTD: KEY EXECUTIVES
TABLE 123. GLAXOSMITHKLINE PHARMACEUTICALS LTD: COMPANY SNAPSHOT
TABLE 124. GLAXOSMITHKLINE PHARMACEUTICALS LTD: PRODUCT SEGMENTS
TABLE 125. GLAXOSMITHKLINE PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
TABLE 126. CHIESI FARMACEUTICI S.P.A.: KEY EXECUTIVES
TABLE 127. CHIESI FARMACEUTICI S.P.A.: COMPANY SNAPSHOT
TABLE 128. CHIESI FARMACEUTICI S.P.A.: PRODUCT SEGMENTS
TABLE 129. CHIESI FARMACEUTICI S.P.A.: PRODUCT PORTFOLIO
TABLE 130. CIPLA LTD.: KEY EXECUTIVES
TABLE 131. CIPLA LTD.: COMPANY SNAPSHOT
TABLE 132. CIPLA LTD.: PRODUCT SEGMENTS
TABLE 133. CIPLA LTD.: PRODUCT PORTFOLIO
TABLE 134. TEVA PHARMACEUTICAL INDUSTRIES: KEY EXECUTIVES
TABLE 135. TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT
TABLE 136. TEVA PHARMACEUTICAL INDUSTRIES: PRODUCT SEGMENTS
TABLE 137. TEVA PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO
TABLE 138. LUPIN: KEY EXECUTIVES
TABLE 139. LUPIN: COMPANY SNAPSHOT
TABLE 140. LUPIN: PRODUCT SEGMENTS
TABLE 141. LUPIN: PRODUCT PORTFOLIO
TABLE 142. LUPIN: KEY STRATERGIES
TABLE 143. APTARGROUP, INC.: KEY EXECUTIVES
TABLE 144. APTARGROUP, INC.: COMPANY SNAPSHOT
TABLE 145. APTARGROUP, INC.: PRODUCT SEGMENTS
TABLE 146. APTARGROUP, INC.: PRODUCT PORTFOLIO
TABLE 147. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
TABLE 148. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 149. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
TABLE 150. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 151. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 152. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 153. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 154. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 155. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 156. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 157. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 158. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. METERED DOSE INHALERS MARKET, 2024-2034
FIGURE 2. SEGMENTATION OF METERED DOSE INHALERS MARKET,2024-2034
FIGURE 3. TOP IMPACTING FACTORS IN METERED DOSE INHALERS MARKET (2023 TO 2034)
FIGURE 4. TOP INVESTMENT POCKETS IN METERED DOSE INHALERS MARKET (2025-2034)
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. MODERATE THREAT OF SUBSTITUTES
FIGURE 8. MODERATE INTENSITY OF RIVALRY
FIGURE 9. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL METERED DOSE INHALERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. METERED DOSE INHALERS MARKET, BY PRODUCT TYPE, 2024 AND 2034(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF METERED DOSE INHALERS MARKET FOR CONVENTIONAL MDIS, BY COUNTRY 2024 AND 2034(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF METERED DOSE INHALERS MARKET FOR BREATH ACTUATED MDIS, BY COUNTRY 2024 AND 2034(%)
FIGURE 14. METERED DOSE INHALERS MARKET, BY APPLICATION, 2024 AND 2034(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF METERED DOSE INHALERS MARKET FOR ASTHMA, BY COUNTRY 2024 AND 2034(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF METERED DOSE INHALERS MARKET FOR COPD, BY COUNTRY 2024 AND 2034(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF METERED DOSE INHALERS MARKET FOR OTHER, BY COUNTRY 2024 AND 2034(%)
FIGURE 18. METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2024 AND 2034(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF METERED DOSE INHALERS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2024 AND 2034(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF METERED DOSE INHALERS MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2024 AND 2034(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF METERED DOSE INHALERS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2024 AND 2034(%)
FIGURE 22. METERED DOSE INHALERS MARKET BY REGION, 2024 AND 2034(%)
FIGURE 23. U.S. METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 24. CANADA METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 25. MEXICO METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 26. GERMANY METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 27. FRANCE METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 28. UK METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 29. ITALY METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 30. SPAIN METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 31. REST OF EUROPE METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 32. JAPAN METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 33. CHINA METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 34. INDIA METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 35. AUSTRALIA METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 36. SOUTH KOREA METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 38. BRAZIL METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 39. SAUDI ARABIA METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 40. SOUTH AFRICA METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 41. REST OF LAMEA METERED DOSE INHALERS MARKET, 2024-2034 ($MILLION)
FIGURE 42. TOP WINNING STRATEGIES, BY YEAR (2022-2025)
FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT (2022-2025)
FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY (2022-2025)
FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 46. COMPETITIVE DASHBOARD
FIGURE 47. COMPETITIVE HEATMAP: METERED DOSE INHALERS MARKET
FIGURE 48. TOP PLAYER POSITIONING, 2024
FIGURE 49. ASTRAZENECA: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 50. ASTRAZENECA: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 51. GLAXOSMITHKLINE PHARMACEUTICALS LTD: NET SALES, 2022-2024 ($MILLION)
FIGURE 52. GLAXOSMITHKLINE PHARMACEUTICALS LTD: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 53. GLAXOSMITHKLINE PHARMACEUTICALS LTD: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 54. CHIESI FARMACEUTICI S.P.A.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 55. CHIESI FARMACEUTICI S.P.A.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 56. CIPLA LTD.: SALES REVENUE, 2022-2024 ($MILLION)
FIGURE 57. CIPLA LTD.: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 58. CIPLA LTD.: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 59. TEVA PHARMACEUTICAL INDUSTRIES: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 60. TEVA PHARMACEUTICAL INDUSTRIES: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 61. LUPIN: NET SALES, 2022-2024 ($MILLION)
FIGURE 62. LUPIN: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 63. LUPIN: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 64. APTARGROUP, INC.: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 65. APTARGROUP, INC.: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 66. APTARGROUP, INC.: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 67. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2022-2024 ($MILLION)
FIGURE 68. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 69. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 70. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 71. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 72. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 73. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 74. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2024 (%)

Companies Mentioned

  • AstraZeneca
  • Cipla Ltd.
  • Teva Pharmaceutical Industries
  • Lupin
  • Boehringer Ingelheim International GmbH
  • Zydus Lifesciences Limited
  • Chiesi Farmaceutici S.p.A.
  • GlaxoSmithKline Pharmaceuticals Ltd
  • AptarGroup, Inc.
  • Sun Pharmaceutical Industries Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Related Topics

Related Reports

Metered Dose Inhaler Devices Market Report 2025 - Product Image

Metered Dose Inhaler Devices Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Albuterol Sulfate Metered Dose Inhalers Market Report 2025 - Product Image

Albuterol Sulfate Metered Dose Inhalers Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Smart Metered-dose Inhaler Market Size & Share, Trends & Forecast to 2034 - Growth Drivers, Challenges & Competitive Landscape - Product Image

Smart Metered-dose Inhaler Market Size & Share, Trends & Forecast to 2034 - Growth Drivers, Challenges & Competitive Landscape

  • Report
  • 150 Pages
  • Global
From
Smart Inhalers Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034) - Product Image

Smart Inhalers Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Metered Dose Inhaler Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Metered Dose Inhaler Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.